However, it did not mean that patients with history or evidence were totally safe to receive IL-17 or IL-23 inhibitors, as patients at high risk or with previous histories of tuberculosis, hepatitis or herpes zoster were already excluded in most studies. This evidence concerns the gene IL17A and tuberculosis.